基于心血管风险与基于血压的降压治疗策略比较:个体参与者数据荟萃分析
该研究利用BPLTTC的11项试验、47,872例个体数据,比较基于预测心血管风险的降压策略与基于收缩压水平的策略。结果显示,风险策略在广泛阈值范围内可减少更多心血管事件,曲线下面积0.71对0.54;相比收缩压≥150 mmHg策略,风险策略需治疗人数少29%或事件少16%。结论支持在中高危个体尤其一级预防中采用心血管风险评估指导降压决策。
要点
- 基于心血管风险的降压策略比单纯基于收缩压的策略更有效。
- 相比收缩压≥150 mmHg策略,风险策略可减少29%治疗人数或增加16%事件预防。
- 风险策略优势在糖尿病或已患心血管病人群中不明显。
核心结论
- 基于预测心血管风险的降压治疗策略在多个阈值范围内比仅基于血压水平的策略更有效。
- 结果支持在中高危个体、尤其一级预防中采用心血管风险评估指导降压决策。
研究设计与样本
- 采用BPLTTC 1995至2013年11项随机试验的个体参与者数据,共47,872例。
- 试验随机分配降压药与安慰剂或强化与较弱降压方案,中位随访4.0年。
- 用多变量Weibull模型估计5年心血管事件风险,比较风险策略与收缩压策略。
主要发现
- 随访期间3,566例(7.5%)发生主要心血管事件。
- 风险策略的曲线下面积为0.71(95%CI 0.70-0.72),收缩压策略为0.54(95%CI 0.53-0.55)。
- 相比治疗所有收缩压≥150 mmHg者,风险策略需治疗人数少29%(95%CI 26%-31%)或事件预防多16%(95%CI 14%-18%)。
- 相比治疗所有收缩压≥140 mmHg者,风险策略需治疗人数少3.8%(95%CI 12.5%少至7.2%多),事件预防多3.1%(95%CI 1.5%-5.0%),但前者无统计学显著性。
- 亚组分析中,风险策略在糖尿病或已患心血管病患者未显示更优。
临床怎么用
- 在中高危个体尤其一级预防中,可考虑用心血管风险评估指导降压治疗决策。
- 基于风险的策略可能减少需治疗人数或增加事件预防,但需结合个体情况。
局限性
- 风险策略在糖尿病或已患心血管病人群中未显示更优。
- 相比收缩压≥140 mmHg策略,需治疗人数减少的估计无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical practice guidelines have traditionally recommended blood pressure treatment based primarily on blood pressure thresholds. In contrast, using predicted cardiovascular risk has been advocated as a more effective strategy to guide treatment decisions for cardiovascular disease (CVD) prevention. We aimed to compare outcomes from a blood pressure-lowering treatment strategy based on predicted cardiovascular risk with one based on systolic blood pressure (SBP) level. METHODS AND FINDINGS: We used individual participant data from the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) from 1995 to 2013. Trials randomly assigned participants to either blood pressure-lowering drugs versus placebo or more intensive versus less intensive blood pressure-lowering regimens. We estimated 5-y risk of CVD events using a multivariable Weibull model previously developed in this dataset. We compared the two strategies at specific SBP thresholds and across the spectrum of risk and blood pressure levels studied in BPLTTC trials. The primary outcome was number of CVD events avoided per persons treated. We included data from 11 trials (47,872 participants). During a median of 4.0 y of follow-up, 3,566 participants (7.5%) experienced a major cardiovascular event. Areas under the curve comparing the two treatment strategies throughout the range of possible thresholds for CVD risk and SBP demonstrated that, on average, a greater number of CVD events would be avoided for a given number of persons treated with the CVD risk strategy compared with the SBP strategy (area under the curve 0.71 [95% confidence interval (CI) 0.70-0.72] for the CVD risk strategy versus 0.54 [95% CI 0.53-0.55] for the SBP strategy). Compared with treating everyone with SBP ≥ 150 mmHg, a CVD risk strategy would require treatment of 29% (95% CI 26%-31%) fewer persons to prevent the same number of events or would prevent 16% (95% CI 14%-18%) more events for the same number of persons treated. Compared with treating everyone with SBP ≥ 140 mmHg, a CVD risk strategy would require treatment of 3.8% (95% CI 12.5% fewer to 7.2% more) fewer persons to prevent the same number of events or would prevent 3.1% (95% CI 1.5%-5.0%) more events for the same number of persons treated, although the former estimate was not statistically significant. In subgroup analyses, the CVD risk strategy did not appear to be more beneficial than the SBP strategy in patients with diabetes mellitus or established CVD. CONCLUSIONS: A blood pressure-lowering treatment strategy based on predicted cardiovascular risk is more effective than one based on blood pressure levels alone across a range of thresholds. These results support using cardiovascular risk assessment to guide blood pressure treatment decision-making in moderate- to high-risk individuals, particularly for primary prevention.
引用
- Karmali KN, Lloyd-Jones DM, van der Leeuw J, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Med. 2018. PMID: 29558462. doi:10.1371/journal.pmed.1002538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。